Recent success in defining the human immunodeficiency virus type 1 (HIV-1) -host cell protein interaction network has provided an opportunity for development of novel antiviral therapeutics targeted to host proteins required for virus infection. This expanded earlier successful development of antagonists for the cellular receptors (CD4) and co-receptors (CCR5 or CXCR4) involved in virus attachment. Induction of the G-alpha q signaling cascade by the HIV-1 envelope is required for virus entry, and it's blocking prevented HIV-1-mediated membrane fusion and initiation of infection. One of the blockers, the Ras inhibitor S-trans, trans-farnesylthiosalicylic acid (FTS), was reported to interfere with HIV-1 infection. Since FTS appears to have an established safety record and is being evaluated (as Salirasib, oral) in phase II human clinical trials for treatment of lung cancer, it was of interest to evaluate the potential of FTS as a topical microbicide for prevention of sexual transmission of HIV-1. Data shown here indicated that this compound did not meet the criteria of an established screening algorithm for evaluation of topical microbicides. Nevertheless, the possibility remains to be explored that FTS (especially when used in combination with other anti-HIV drugs) might be useful in sustained pre-exposure prophylaxis to prevent HIV-1 transmission.
Introduction
The global AIDS epidemic has proceeded without abatement for about 30 years with about 36 million people having chronic HIV-1 infections and about 36 million who already succumbed to AIDS. Most new infections have been acquired by the mucosal route, heterosexual transmission playing the major (~80%) role. Anti-HIV-1 vaccines applicable to global immunization programs are not expected to become available for many years. Therefore, other prevention strategies are needed, i.e. mechanical or chemical barrier methods. The latter correspond to microbicides, topical formulations expected to block HIV-1 infection (and possibly also transmission of other sexually transmitted pathogens) when applied vaginally or rectally before intercourse. Several large-scale phase III efficacy trials of candidate microbicide formulations failed to demonstrate efficacy. Therefore, additional research and development in the microbicide field is needed ( 
Materials and Methods

Cells and virus
MAGI-CCR5 cells
Data analysis and quality control
For each assay, IC 50 , IC 90 and TC 50 values were calculated using regression analysis. The Therapeutic Index (TI) was calculated as TC 50 /IC 50 . All assays passed internal quality standards established at the Sothern Research Institute, Frederick, MD 21701. This included quality of replicates, endpoint signal and performance of assay controls.
Solutions of the latter compound were prepared as follows: 1. FTS was dissolved in 100% dimethylsulfoxide (DMSO) to a stock concentration of 40mM by adding 0.2022 mL DMSO to 2.9 mg FTS. 2. Another stock solution was prepared by first dissolving 0.7 mg FTS in ethanol and then adding an equal volume of phosphate buffered saline (PBS) to achieve a final concentration of 0.5 mg/mL (=1.4 mM). 3. FTS was fully soluble using both methods. 4. For the assays, each stock solution was used to prepare 2x concentrated working solutions and serial dilutions were prepared starting from a final concentration of 100 µM. The diluents, DMSO and ethanol-PBS (1:1) were also tested as controls in the assays at the same concentration as that used for the test material. Log 10 dilutions of all working solutions of test article or diluent control were prepared for testing.
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Assays for inhibition of HIV-1 infection
The assays were performed as descried earlier (Lackman-Smith et al., 2008). Briefly, 24 hours prior to initiation of the assay, the cells were trypsinized, counted, and plated in 96-well flat bottom wells at 1 x 10 4 cells per well. Medium was removed and diluted test article or diluent controls in medium placed on the cells, and incubated for 15 min at 37ºC. Ten (10) TCID 50 of the BaL strain of HIV-1 was then added to the wells and the plates were incubated for 40 to 48 h at 37 °C. At termination of the assay, media was removed and β-galactosidase enzyme expression determined by chemiluminescence per the manufacturer's instructions (Tropix Gal-screen β, Applied Biosystems, Bedford, MA 01730). TAK-779 and AMD3100 were the positive and negative control compounds respectively for the assay. Toxicity using CellTiter96® Reagent (Promega, Fitchburg, WI 53711) was tested in parallel with tests for inhibition of HIV-1 infection. All assays were performed in triplicate and mean values were calculated.
Results
To confirm the proper performance of infectivity assays, the inhibitory effect of the CCR5 antagonist TAK 779 on infection The FTS stock solution (40 mM) was prepared in DMSO. The effect of DMSO alone on virus infection and its cytotoxicity were determined at final concentrations corresponding to those of FTS dilutions (top panel). The scales on the ordinates of each panel correspond to both %VC and %CC. MAGI-CCR5 cells, expressing CD4, the HIV-1 co-receptor CCR5, and beta-galactosidase under the control of the HIV-1 long terminal repeat (LTR), were used. HIV-1 BaL uses the CCR5 co-receptor (= R5 tropic), and TAK 779 is a specific CCR5 antagonist while AMD 3100, used as a "negative" control, is a CXCR4 antagonist. Virus infection was monitored by chemiluminometric quantitation of beta-galactosidase (relative quantity corresponding to infection in the absence of any compounds listed above = 100%). Cytotoxicity was determined using the CellTiter Reagent (Promega). Absorbance measured by the assay is directly proportional to the number of living cells in culture (=100%). The CXCR4 antagonist AMD 3100 had, in comparison, marginal effects, as expected (IC 50 = >10 µM).
FTS was even less inhibitory than AMD 3100 ( Figure 2 , top panel; IC 50 = >100 µM). These results were obtained using a stock solution of FTS prepared in DMSO. The medium containing DMSO only had no detectable inhibitory effects. Similar results were obtained with an FTS stock solution prepared in an ethanol-PBS mixture (data not shown).
In conclusion, the inhibitory activity of FTS on HIV-1 BaL infection was too low for further consideration of this compound for inclusion into topical microbicide formulations.
Discussion
The inhibition of HIV-1 BaL infection of the MAGI-CCR5 target cells by FTS was unimpressive (~40% inhibition at a 100 µM concentration) but significant in comparison with that attributable only to the diluent containing DMSO (Figure 2 , top panel). The observed inhibition could not have been caused by cytotoxic effects of the compound. Nevertheless, these data suggest that FTS does not meet criteria for further development as a topical microbicide. These results merit further discussion, and should not discourage from additional research regarding the potential application of FTS for pre-exposure prophylaxis.
Results of earlier experiments (Harmon and Ratner, 2008) showed that FTS at a 50 µM concentration caused a 99.7 +/-2 % inhibition of infection. The R5 virus HIV YU2 and TZM-BL cells were used in these experiments. More significantly, the cells were pre-incubated with FTS for 1 hr prior to the addition of virus, as compared with 15 min in the experiments described in the Results section. An appropriate duration of pre-exposure to a compound targeted to host cell proteins before exposure to HIV-1 is likely to be required for optimal expression of antiviral activity. In this respect it should also be mentioned that inhibition of Ras activation by FTS and other compounds was performed with serum-starved cells (Harmon and Ratner, 2008 ). This was not so when inhibition of HIV-1 infection was measured. Pre-exposure to compound with anti-HIV-1 activity for 1 hr or longer is impractical for topical microbicides to be applied vaginally or rectally before intercourse. Journal of Antivirals & Antiretrovirals -Open Access JAA/Vol.1 Issue. 2 Animal model experiments will be required in order to investigate further the potential of FTS for anti-HIV-1 prophylaxis.
